The reasons why doses are not individualised routinely are difficulties in defining , predicting and achieving an optimal fluorouracil exposure or dose because of a narrow therapeutic index , nonlinear pharmacokinetics , variabilities in administration rates and metabolism , and in targets like thymidylate synthase .